$Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation$

Moderately Hypofractionated Radiotherapy with Simultaneous Integrated Boost in Prostate Cancer: A Comparative Study with Conventionally Fractionated Radiation

Background. To report 5-year clinical outcomes and toxicity in organ-confined prostate cancer (PCa) for low- and intermediate-risk patients treated with a moderately hypofractionated schedule of radiotherapy (RT) delivered with simultaneous integrated boost (SIB) compared to a conventionally fractio...

Full description

Bibliographic Details
Main Authors:	Domenico Cante, Cristina Piva, Edoardo T. F. Petrucci, Piera Sciacero, Silvia Ferrario, Massimo Pasquino, Valeria Casanova Borca, Maria R. La Porta, Pierfrancesco Franco
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	Journal of Oncology
Online Access:	http://dx.doi.org/10.1155/2020/3170396

Similar Items

Concurrent Boost with Adjuvant Breast Hypofractionated Radiotherapy and Toxicity Assessment
by: Mona M. Sayed, et al.
Published: (2015-01-01)

Head and neck region consolidation radiotherapy and prophylactic cranial irradiation with hippocampal avoidance delivered with helical tomotherapy after induction chemotherapy for non-sinonasal neuroendocrine carcinoma of the upper airways
by: Franco Pierfrancesco, et al.
Published: (2012-02-01)

Hypofractionated Proton Boost Combined with External Beam Radiotherapy for Treatment of Localized Prostate Cancer
by: Silvia Johansson, et al.
Published: (2012-01-01)

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
by: Jeong Hoon Phak, et al.
Published: (2016-03-01)

Does TomoDirect 3DCRT represent a suitable option for post-operative whole breast irradiation? A hypothesis-generating pilot study
by: Borca Valeria Casanova, et al.
Published: (2012-12-01)

HYPOFRACTIONATED RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME
by: Sadaf Usman, et al.
Published: (2015-11-01)

Hypofractionated radiotherapy for breast cancer
by: Haviland, J.S, et al.
Published: (2010)

Are we ready to use hypofractionated instead of conventional radiotherapy for prostate cancer? Not yet
by: Antonio Cassio Assis Pellizzon

A comparative study of hypofractionated and conventional radiotherapy in postmastectomy breast cancer patients
by: Kartick Rastogi, et al.
Published: (2018-01-01)

Quantitative MRI Changes During Weekly Ultra-Hypofractionated Prostate Cancer Radiotherapy With Integrated Boost
by: Marcel A. van Schie, et al.
Published: (2019-12-01)

Comparison  of  efficacy, safety, and costs between neoadjuvant hypofractionated radiotherapy and conventionally fractionated radiotherapy for esophageal carcinoma
by: Jiahua Lyu, et al.
Published: (2019-07-01)

Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience
by: Liangzhi Zhong, et al.
Published: (2019-06-01)

Role of hypofractionated tumor bed boost in the era of short course radiotherapy in early stage breast cancer
by: A. Pandey, et al.
Published: (2021-04-01)

Hypofractionated Radiotherapy in African Cancer Centers
by: William Swanson, et al.
Published: (2021-02-01)

Cost Minimization Analysis of Hypofractionated Radiotherapy
by: Hannah L. Yaremko, et al.
Published: (2021-01-01)

Short Course Hypofractionated Radiotherapy versus Conventional Radiotherapy for Poor Prognosis Glioblastoma Multiforme: A Randomised Controlled Trial
by: SUNIL CHOUDHARY, et al.
Published: (2019-03-01)

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis
by: Dong-Yun Kim, et al.
Published: (2021-02-01)

Conventional versus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity
by: Imjai Chitapanarux, et al.
Published: (2019-10-01)

Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment
by: Lee Dong, et al.
Published: (2012-06-01)

Early toxicity of hypofractionated radiotherapy for prostate cancer
by: Pavel Krupa, et al.
Published: (2016-09-01)

Hypofractionated whole breast radiotherapy: current perspectives
by: Koulis TA, et al.
Published: (2015-10-01)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
by: L. Chinsoo Cho, et al.
Published: (2013-01-01)

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review
by: Lei Liu, et al.
Published: (2020-01-01)

Randomized Prospective Study Comparing Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node-Positive Breast Cancer
by: Mai Atef, et al.
Published: (2019-12-01)

Acute toxicity in moderate hypofractionation with Simultaneous Integrated Boost (SIB) radiation therapy for prostate cancer: A prospective study
by: F. Kraja, et al.
Published: (2020-11-01)

Hypofractionated Image-Guided Radiation Therapy With Simultaneous-Integrated Boost Technique for Limited Metastases: A Multi-Institutional Analysis
by: Corbin D. Jacobs, et al.
Published: (2019-06-01)

Extreme Hypofractionated Image-Guided Radiotherapy for Prostate Cancer
by: Carlo Greco
Published: (2013-09-01)

Hypofractionated radiotherapy has the potential for second cancer reduction
by: Besserer Jürgen, et al.
Published: (2010-02-01)

Hypofractionated Prostate Radiotherapy with or without Conventionally Fractionated Nodal Irradiation: Clinical Toxicity Observations and Retrospective Daily Dosimetry
by: Andrew M. McDonald, et al.
Published: (2012-01-01)

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
by: Andrei Fodor, et al.
Published: (2021-02-01)

Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials
by: Wei Guo, et al.
Published: (2019-11-01)

Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial
by: Lucas C. Mendez, et al.
Published: (2020-10-01)

Comparing the effects of conventional and hypofractionated radiotherapies on early skin toxicity and cosmetic outcomes after breast cancer conserving surgery
by: Amouzegar Hashemi F, et al.
Published: (2012-12-01)

A retrospective study of hypofractionated radiotherapy for keloids in 100 cases
by: Ping Wen, et al.
Published: (2021-02-01)

Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?
by: Sean Mahase, et al.
Published: (2020-12-01)

Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma
by: Julian Biau, et al.
Published: (2017-07-01)

Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
by: Charalambos Zambatis, et al.
Published: (1998-01-01)

Evolution of Hypofractionated Accelerated Radiotherapy for Prostate Cancer – The Sunnybrook Experience
by: Hima Bindu Musunuru, et al.
Published: (2014-11-01)

An Extended Hypofractionated Palliative Radiotherapy Regimen for Head and Neck Carcinomas
by: Michael Laursen, et al.
Published: (2018-06-01)

Hypofractionated conformal stereotactic radiotherapy in the treatment of AVMs and cerebral metastases
by: Lindvall, Peter
Published: (2006)